Advertisement

Topics

LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®

08:45 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
LabCorp Performed Testing for Studies Supporting Approval of Two New Complementary Diagnostic Indications in Connection with the Treatment of Bladder Cancer and Cancer of the Head and Neck LabCorp (NYSE: LH) a leading global...

Other Sources for this Article

LabCorp
Media Contact:
Donald Von Hagen, 336-436-8263
or
Investor Contact:
Scott Frommer, 336-436-5076

NEXT ARTICLE

More From BioPortfolio on "LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...